Cyclacel Pharmaceuticals, Inc. CYCC
We take great care to ensure that the data presented and summarized in this overview for Cyclacel Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CYCC
Top Purchases
Top Sells
About CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Insider Transactions at CYCC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 29
2024
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+45.12%
|
-
|
Dec 21
2023
|
Spiro George Rombotis President and CEO |
BUY
Open market or private purchase
|
Direct |
6,070
+8.12%
|
$18,210
$3.31 P/Share
|
Dec 21
2023
|
Paul Mc Barron Director |
BUY
Open market or private purchase
|
Direct |
1,886
+5.35%
|
$5,658
$3.31 P/Share
|
Jun 30
2023
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.32%
|
-
|
Jun 30
2023
|
Christopher S Henney Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+35.0%
|
-
|
Jun 30
2023
|
Kenneth M. Ferguson Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+32.07%
|
-
|
Jun 30
2023
|
Karin L Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.32%
|
-
|
Jun 30
2023
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+35.0%
|
-
|
Jun 30
2023
|
Sam L Barker Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.43%
|
-
|
Jan 31
2023
|
Paul Mc Barron Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+49.77%
|
-
|
Jan 31
2023
|
Mark Kirschbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+50.0%
|
-
|
Jan 31
2023
|
Spiro George Rombotis President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
57,600
+47.92%
|
-
|
Jun 14
2022
|
Sam L Barker Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+45.18%
|
-
|
Jun 14
2022
|
Christopher S Henney Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
Jun 14
2022
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+44.94%
|
-
|
Jun 14
2022
|
Lloyd Sems Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
Jun 14
2022
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
Jun 14
2022
|
Karin L Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+44.94%
|
-
|
Jun 14
2022
|
Kenneth M. Ferguson Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,733
+50.0%
|
-
|
Nov 30
2021
|
Sam L Barker Director |
SELL
Open market or private sale
|
Direct |
12
-0.35%
|
$36
$3.57 P/Share
|
Last 12 Months Summary
Open market or private purchase | 7.96K shares |
---|---|
Grant, award, or other acquisition | 12.5K shares |